Jitsubo

Executive Summary

Jitsubo is a Japanese biotechnology company focused on peptide manufacturing through its proprietary Molecular Hiving™ technology, a tag-assisted liquid-phase peptide synthesis platform. Founded in 2020 and based in Minoh, the company offers contract development and manufacturing services (CDMO) for peptide therapeutics, targeting metabolic disorders such as diabetes and obesity. Operating in the platform stage with 10-50 employees, Jitsubo leverages its efficient synthesis platform to address growing demand for high-quality peptides in the pharmaceutical industry. The global peptide therapeutics market is expanding, driven by the success of GLP-1 agonists and other metabolic drugs. Jitsubo's Molecular Hiving™ technology positions it to offer cost-effective and scalable production solutions, potentially attracting partnerships with biotech and pharma companies. As a private entity without disclosed financials or revenue, the company's near-term outlook depends on securing manufacturing contracts and advancing its technology platform. With a differentiated approach to peptide synthesis, Jitsubo is well-placed to capture a share of the CDMO market, though execution risks remain given its early stage.

Upcoming Catalysts (preview)

• TBDFirst major CDMO partnership with a pharmaceutical company65% success
• TBDSeries A funding round to scale manufacturing capacity60% success
• TBDPublication or validation of Molecular Hiving™ platform in peer-reviewed journal70% success